Global Cancer Companion Diagnostic Supply, Demand and Key Producers, 2023-2029

October 2023 | 102 pages | ID: G8B5376A990DEN
GlobalInfoResearch

Abstracts

The global Cancer Companion Diagnostic market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.

Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient's therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.

This report studies the global Cancer Companion Diagnostic demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Cancer Companion Diagnostic, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cancer Companion Diagnostic that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Cancer Companion Diagnostic total market, 2018-2029, (USD Million)

Global Cancer Companion Diagnostic total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Cancer Companion Diagnostic total market, key domestic companies and share, (USD Million)

Global Cancer Companion Diagnostic revenue by player and market share 2018-2023, (USD Million)

Global Cancer Companion Diagnostic total market by Type, CAGR, 2018-2029, (USD Million)

Global Cancer Companion Diagnostic total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Cancer Companion Diagnostic market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AmoyDx, Novogene, Illumina, Roche, Agilent, Abbott, Thermo Fisher, Qiagen and Guardant Health, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Cancer Companion Diagnostic market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Cancer Companion Diagnostic Market, By Region:

• United States
• China
• Europe
• Japan
• South Korea
• ASEAN
• India
• Rest of World

Global Cancer Companion Diagnostic Market, Segmentation by Type

• Polymerase Chain Reaction (PCR)
• “Next Generation” Sequencing (NGS)
• Fluorescence In Situ Hybridization (FISH)
• Immunohistochemistry (IHC)

Global Cancer Companion Diagnostic Market, Segmentation by Application

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Others

Companies Profiled:

• AmoyDx
• Novogene
• Illumina
• Roche
• Agilent
• Abbott
• Thermo Fisher
• Qiagen
• Guardant Health

Key Questions Answered

1. How big is the global Cancer Companion Diagnostic market?

2. What is the demand of the global Cancer Companion Diagnostic market?

3. What is the year over year growth of the global Cancer Companion Diagnostic market?

4. What is the total value of the global Cancer Companion Diagnostic market?

5. Who are the major players in the global Cancer Companion Diagnostic market?

Contents

1 SUPPLY SUMMARY

1.1 Cancer Companion Diagnostic Introduction
1.2 World Cancer Companion Diagnostic Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Cancer Companion Diagnostic Total Market by Region (by Headquarter Location)
  1.3.1 World Cancer Companion Diagnostic Market Size by Region (2018-2029), (by Headquarter Location)
  1.3.2 United States Cancer Companion Diagnostic Market Size (2018-2029)
  1.3.3 China Cancer Companion Diagnostic Market Size (2018-2029)
  1.3.4 Europe Cancer Companion Diagnostic Market Size (2018-2029)
  1.3.5 Japan Cancer Companion Diagnostic Market Size (2018-2029)
  1.3.6 South Korea Cancer Companion Diagnostic Market Size (2018-2029)
  1.3.7 ASEAN Cancer Companion Diagnostic Market Size (2018-2029)
  1.3.8 India Cancer Companion Diagnostic Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Cancer Companion Diagnostic Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Cancer Companion Diagnostic Major Market Trends

2 DEMAND SUMMARY

2.1 World Cancer Companion Diagnostic Consumption Value (2018-2029)
2.2 World Cancer Companion Diagnostic Consumption Value by Region
  2.2.1 World Cancer Companion Diagnostic Consumption Value by Region (2018-2023)
  2.2.2 World Cancer Companion Diagnostic Consumption Value Forecast by Region (2024-2029)
2.3 United States Cancer Companion Diagnostic Consumption Value (2018-2029)
2.4 China Cancer Companion Diagnostic Consumption Value (2018-2029)
2.5 Europe Cancer Companion Diagnostic Consumption Value (2018-2029)
2.6 Japan Cancer Companion Diagnostic Consumption Value (2018-2029)
2.7 South Korea Cancer Companion Diagnostic Consumption Value (2018-2029)
2.8 ASEAN Cancer Companion Diagnostic Consumption Value (2018-2029)
2.9 India Cancer Companion Diagnostic Consumption Value (2018-2029)

3 WORLD CANCER COMPANION DIAGNOSTIC COMPANIES COMPETITIVE ANALYSIS

3.1 World Cancer Companion Diagnostic Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global Cancer Companion Diagnostic Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for Cancer Companion Diagnostic in 2022
  3.2.3 Global Concentration Ratios (CR8) for Cancer Companion Diagnostic in 2022
3.3 Cancer Companion Diagnostic Company Evaluation Quadrant
3.4 Cancer Companion Diagnostic Market: Overall Company Footprint Analysis
  3.4.1 Cancer Companion Diagnostic Market: Region Footprint
  3.4.2 Cancer Companion Diagnostic Market: Company Product Type Footprint
  3.4.3 Cancer Companion Diagnostic Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Cancer Companion Diagnostic Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: Cancer Companion Diagnostic Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
  4.1.2 United States VS China: Cancer Companion Diagnostic Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Cancer Companion Diagnostic Consumption Value Comparison
  4.2.1 United States VS China: Cancer Companion Diagnostic Consumption Value Comparison (2018 & 2022 & 2029)
  4.2.2 United States VS China: Cancer Companion Diagnostic Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Cancer Companion Diagnostic Companies and Market Share, 2018-2023
  4.3.1 United States Based Cancer Companion Diagnostic Companies, Headquarters (States, Country)
  4.3.2 United States Based Companies Cancer Companion Diagnostic Revenue, (2018-2023)
4.4 China Based Companies Cancer Companion Diagnostic Revenue and Market Share, 2018-2023
  4.4.1 China Based Cancer Companion Diagnostic Companies, Company Headquarters (Province, Country)
  4.4.2 China Based Companies Cancer Companion Diagnostic Revenue, (2018-2023)
4.5 Rest of World Based Cancer Companion Diagnostic Companies and Market Share, 2018-2023
  4.5.1 Rest of World Based Cancer Companion Diagnostic Companies, Headquarters (States, Country)
  4.5.2 Rest of World Based Companies Cancer Companion Diagnostic Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Cancer Companion Diagnostic Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
  5.2.1 Polymerase Chain Reaction (PCR)
  5.2.2 “Next Generation” Sequencing (NGS)
  5.2.3 Fluorescence In Situ Hybridization (FISH)
  5.2.4 Immunohistochemistry (IHC)
5.3 Market Segment by Type
  5.3.1 World Cancer Companion Diagnostic Market Size by Type (2018-2023)
  5.3.2 World Cancer Companion Diagnostic Market Size by Type (2024-2029)
  5.3.3 World Cancer Companion Diagnostic Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Cancer Companion Diagnostic Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
  6.2.1 Lung Cancer
  6.2.2 Colorectal Cancer
  6.2.3 Breast Cancer
  6.2.4 Others
  6.2.5 Others
6.3 Market Segment by Application
  6.3.1 World Cancer Companion Diagnostic Market Size by Application (2018-2023)
  6.3.2 World Cancer Companion Diagnostic Market Size by Application (2024-2029)
  6.3.3 World Cancer Companion Diagnostic Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 AmoyDx
  7.1.1 AmoyDx Details
  7.1.2 AmoyDx Major Business
  7.1.3 AmoyDx Cancer Companion Diagnostic Product and Services
  7.1.4 AmoyDx Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.1.5 AmoyDx Recent Developments/Updates
  7.1.6 AmoyDx Competitive Strengths & Weaknesses
7.2 Novogene
  7.2.1 Novogene Details
  7.2.2 Novogene Major Business
  7.2.3 Novogene Cancer Companion Diagnostic Product and Services
  7.2.4 Novogene Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.2.5 Novogene Recent Developments/Updates
  7.2.6 Novogene Competitive Strengths & Weaknesses
7.3 Illumina
  7.3.1 Illumina Details
  7.3.2 Illumina Major Business
  7.3.3 Illumina Cancer Companion Diagnostic Product and Services
  7.3.4 Illumina Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.3.5 Illumina Recent Developments/Updates
  7.3.6 Illumina Competitive Strengths & Weaknesses
7.4 Roche
  7.4.1 Roche Details
  7.4.2 Roche Major Business
  7.4.3 Roche Cancer Companion Diagnostic Product and Services
  7.4.4 Roche Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.4.5 Roche Recent Developments/Updates
  7.4.6 Roche Competitive Strengths & Weaknesses
7.5 Agilent
  7.5.1 Agilent Details
  7.5.2 Agilent Major Business
  7.5.3 Agilent Cancer Companion Diagnostic Product and Services
  7.5.4 Agilent Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.5.5 Agilent Recent Developments/Updates
  7.5.6 Agilent Competitive Strengths & Weaknesses
7.6 Abbott
  7.6.1 Abbott Details
  7.6.2 Abbott Major Business
  7.6.3 Abbott Cancer Companion Diagnostic Product and Services
  7.6.4 Abbott Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.6.5 Abbott Recent Developments/Updates
  7.6.6 Abbott Competitive Strengths & Weaknesses
7.7 Thermo Fisher
  7.7.1 Thermo Fisher Details
  7.7.2 Thermo Fisher Major Business
  7.7.3 Thermo Fisher Cancer Companion Diagnostic Product and Services
  7.7.4 Thermo Fisher Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.7.5 Thermo Fisher Recent Developments/Updates
  7.7.6 Thermo Fisher Competitive Strengths & Weaknesses
7.8 Qiagen
  7.8.1 Qiagen Details
  7.8.2 Qiagen Major Business
  7.8.3 Qiagen Cancer Companion Diagnostic Product and Services
  7.8.4 Qiagen Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.8.5 Qiagen Recent Developments/Updates
  7.8.6 Qiagen Competitive Strengths & Weaknesses
7.9 Guardant Health
  7.9.1 Guardant Health Details
  7.9.2 Guardant Health Major Business
  7.9.3 Guardant Health Cancer Companion Diagnostic Product and Services
  7.9.4 Guardant Health Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
  7.9.5 Guardant Health Recent Developments/Updates
  7.9.6 Guardant Health Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

8.1 Cancer Companion Diagnostic Industry Chain
8.2 Cancer Companion Diagnostic Upstream Analysis
8.3 Cancer Companion Diagnostic Midstream Analysis
8.4 Cancer Companion Diagnostic Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION


10 APPENDIX

10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Cancer Companion Diagnostic Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Cancer Companion Diagnostic Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Cancer Companion Diagnostic Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Cancer Companion Diagnostic Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Cancer Companion Diagnostic Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Cancer Companion Diagnostic Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Cancer Companion Diagnostic Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Cancer Companion Diagnostic Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Cancer Companion Diagnostic Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Cancer Companion Diagnostic Players in 2022
Table 12. World Cancer Companion Diagnostic Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Cancer Companion Diagnostic Company Evaluation Quadrant
Table 14. Head Office of Key Cancer Companion Diagnostic Player
Table 15. Cancer Companion Diagnostic Market: Company Product Type Footprint
Table 16. Cancer Companion Diagnostic Market: Company Product Application Footprint
Table 17. Cancer Companion Diagnostic Mergers & Acquisitions Activity
Table 18. United States VS China Cancer Companion Diagnostic Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Cancer Companion Diagnostic Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Cancer Companion Diagnostic Companies, Headquarters (States, Country)
Table 21. United States Based Companies Cancer Companion Diagnostic Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Cancer Companion Diagnostic Revenue Market Share (2018-2023)
Table 23. China Based Cancer Companion Diagnostic Companies, Headquarters (Province, Country)
Table 24. China Based Companies Cancer Companion Diagnostic Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Cancer Companion Diagnostic Revenue Market Share (2018-2023)
Table 26. Rest of World Based Cancer Companion Diagnostic Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Cancer Companion Diagnostic Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Cancer Companion Diagnostic Revenue Market Share (2018-2023)
Table 29. World Cancer Companion Diagnostic Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Cancer Companion Diagnostic Market Size by Type (2018-2023) & (USD Million)
Table 31. World Cancer Companion Diagnostic Market Size by Type (2024-2029) & (USD Million)
Table 32. World Cancer Companion Diagnostic Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Cancer Companion Diagnostic Market Size by Application (2018-2023) & (USD Million)
Table 34. World Cancer Companion Diagnostic Market Size by Application (2024-2029) & (USD Million)
Table 35. AmoyDx Basic Information, Area Served and Competitors
Table 36. AmoyDx Major Business
Table 37. AmoyDx Cancer Companion Diagnostic Product and Services
Table 38. AmoyDx Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. AmoyDx Recent Developments/Updates
Table 40. AmoyDx Competitive Strengths & Weaknesses
Table 41. Novogene Basic Information, Area Served and Competitors
Table 42. Novogene Major Business
Table 43. Novogene Cancer Companion Diagnostic Product and Services
Table 44. Novogene Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novogene Recent Developments/Updates
Table 46. Novogene Competitive Strengths & Weaknesses
Table 47. Illumina Basic Information, Area Served and Competitors
Table 48. Illumina Major Business
Table 49. Illumina Cancer Companion Diagnostic Product and Services
Table 50. Illumina Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Illumina Recent Developments/Updates
Table 52. Illumina Competitive Strengths & Weaknesses
Table 53. Roche Basic Information, Area Served and Competitors
Table 54. Roche Major Business
Table 55. Roche Cancer Companion Diagnostic Product and Services
Table 56. Roche Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Roche Recent Developments/Updates
Table 58. Roche Competitive Strengths & Weaknesses
Table 59. Agilent Basic Information, Area Served and Competitors
Table 60. Agilent Major Business
Table 61. Agilent Cancer Companion Diagnostic Product and Services
Table 62. Agilent Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Agilent Recent Developments/Updates
Table 64. Agilent Competitive Strengths & Weaknesses
Table 65. Abbott Basic Information, Area Served and Competitors
Table 66. Abbott Major Business
Table 67. Abbott Cancer Companion Diagnostic Product and Services
Table 68. Abbott Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Abbott Recent Developments/Updates
Table 70. Abbott Competitive Strengths & Weaknesses
Table 71. Thermo Fisher Basic Information, Area Served and Competitors
Table 72. Thermo Fisher Major Business
Table 73. Thermo Fisher Cancer Companion Diagnostic Product and Services
Table 74. Thermo Fisher Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Thermo Fisher Recent Developments/Updates
Table 76. Thermo Fisher Competitive Strengths & Weaknesses
Table 77. Qiagen Basic Information, Area Served and Competitors
Table 78. Qiagen Major Business
Table 79. Qiagen Cancer Companion Diagnostic Product and Services
Table 80. Qiagen Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Qiagen Recent Developments/Updates
Table 82. Guardant Health Basic Information, Area Served and Competitors
Table 83. Guardant Health Major Business
Table 84. Guardant Health Cancer Companion Diagnostic Product and Services
Table 85. Guardant Health Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 86. Global Key Players of Cancer Companion Diagnostic Upstream (Raw Materials)
Table 87. Cancer Companion Diagnostic Typical Customers
List of Figure
Figure 1. Cancer Companion Diagnostic Picture
Figure 2. World Cancer Companion Diagnostic Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Cancer Companion Diagnostic Total Market Size (2018-2029) & (USD Million)
Figure 4. World Cancer Companion Diagnostic Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Cancer Companion Diagnostic Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Cancer Companion Diagnostic Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Cancer Companion Diagnostic Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Cancer Companion Diagnostic Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Cancer Companion Diagnostic Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Cancer Companion Diagnostic Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Cancer Companion Diagnostic Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Cancer Companion Diagnostic Revenue (2018-2029) & (USD Million)
Figure 13. Cancer Companion Diagnostic Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 16. World Cancer Companion Diagnostic Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 18. China Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 23. India Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Cancer Companion Diagnostic by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Cancer Companion Diagnostic Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Cancer Companion Diagnostic Markets in 2022
Figure 27. United States VS China: Cancer Companion Diagnostic Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Cancer Companion Diagnostic Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Cancer Companion Diagnostic Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Cancer Companion Diagnostic Market Size Market Share by Type in 2022
Figure 31. Polymerase Chain Reaction (PCR)
Figure 32. “Next Generation” Sequencing (NGS)
Figure 33. Fluorescence In Situ Hybridization (FISH)
Figure 34. Immunohistochemistry (IHC)
Figure 35. World Cancer Companion Diagnostic Market Size Market Share by Type (2018-2029)
Figure 36. World Cancer Companion Diagnostic Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Cancer Companion Diagnostic Market Size Market Share by Application in 2022
Figure 38. Lung Cancer
Figure 39. Colorectal Cancer
Figure 40. Breast Cancer
Figure 41. Others
Figure 42. Cancer Companion Diagnostic Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source